Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OPTOGENERAPY

Financiado

Cerrado

Optogenetic Protein Therapy for Multiple Sclerosis

Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment. The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously... ver más

31/01/2020

EURECAT

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

FUNDACIO EURECAT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 58M€

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-01-31

NMBP-09-2016: Biomaterials for diagnosis and trea...

I+D

Cerrada hace 9 años

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

EURECAT

1.26M€ | Lider

ICE CREAM FACTORY CO MAKER

398.39K€ | Participante

TUL

255.00K€ | Participante

EUR

322.59K€ | Participante

Proyectos interesantes

NANOTECNOLOGÍA PARA LA LIBERACIÓN CONTROLADA...

Medical Technol...

Nanotechnology

507K€ Cerrado

POLYBRAINT

Medical Technol...

Nanotechnology

150K€ Cerrado

RYC2018-025617-I

Medical Technol...

Nanotechnology

309K€ Cerrado

MusclePlate

Medical Technol...

Biotechnology

150K€ Cerrado

FJCI-2016-28911

Medical Technol...

Health Informat...

50K€ Cerrado

VACUNA TERAPEUTICA PARA EL TRATAMIENTO DEL SI...

Medical Technol...

Biotechnology

837K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 38 meses Fecha Inicio: 2016-11-23
Fecha Fin: 2020-01-31

Líder del proyecto

FUNDACIO EURECAT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 58M€

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment. The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months. The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed. At the same time, this membrane acts to prevent immune rejection and offers long-term safety in drug release while overcoming the adverse effects of current cellular therapies. Wireless powered optogenetics – light controlling the cellular response of genetically engineered cells – is used to control the production of IFN-ß. Replacing standard intravenous IFN-ß delivery by subcutaneous delivery prevents short and long term side effects and efficiency-losses related to drug peaks and discontinuation, while saving non-adherence costs. It is a low-cost system enabling large scale manufacturing and reduction of time to market up to 30% compared to other cell therapies, combining: - Polymeric biomaterials with strong optical, biocompatibility and barrier requirements, to build the cell chamber and to encapsulate the optoelectronics. - Optoelectronics miniaturization, autonomy and optical performance. - Optimal cellular engineering design, enhanced by computer modelling, for stability and performance of the synthetic optogenetic gene pathway over long-term implantation. - Micro moulding enabling optoelectronics and membrane embedding for safety and minimal invasiveness. The innovation potential is so huge that a proof-of-concept was listed by Scientist Magazine as one of the 2014’s big advances in science. In our top-class consortium, industrial pull meets technological push, ensuring that the preclinically validated prototype obtained at the end responds to market demands. BOSTON SCIENTIFIC, worldwide leader in neuromodulation active implants, has clear exploitation plans and high market penetration potential. 4 research intensive SMEs: TWO, GENEXPLAIN, NEOS and ULTRASION bring specific competences while increasing their own competitiveness.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores